These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30394160)

  • 1.
    Tong Z; Yerramilli U; Yao S; Young JD; Hoffmann M; Surapaneni S
    Xenobiotica; 2019 Oct; 49(10):1229-1236. PubMed ID: 30394160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine.
    Damaraju VL; Mowles D; Yao S; Ng A; Young JD; Cass CE; Tong Z
    Nucleosides Nucleotides Nucleic Acids; 2012; 31(3):236-55. PubMed ID: 22356238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
    DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
    Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validated LC-MS/MS Method for Simultaneous Quantitation of Enasidenib and its Active Metabolite, AGI-16903 in Small Volume Mice Plasma: Application to a Pharmacokinetic Study.
    Dittakavi S; Hallur G; Purra BR; Kiran V; Zakkula A; Mullangi R
    Drug Res (Stuttg); 2020 Jan; 70(1):41-48. PubMed ID: 31652462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters.
    Yamamoto T; Kuniki K; Takekuma Y; Hirano T; Iseki K; Sugawara M
    Eur J Pharmacol; 2007 Feb; 557(1):1-8. PubMed ID: 17140564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal nucleoside transporters: physiological and clinical implications.
    Elwi AN; Damaraju VL; Baldwin SA; Young JD; Sawyer MB; Cass CE
    Biochem Cell Biol; 2006 Dec; 84(6):844-58. PubMed ID: 17215872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Cheng Y; Wang X; Tong Z; Reyes J; Carayannopoulos L; Zhou S; Li Y
    J Clin Pharmacol; 2022 Apr; 62(4):494-504. PubMed ID: 34617279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
    Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
    Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
    Fathi AT; DiNardo CD; Kline I; Kenvin L; Gupta I; Attar EC; Stein EM; de Botton S;
    JAMA Oncol; 2018 Aug; 4(8):1106-1110. PubMed ID: 29346478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2.
    Dutta R; Zhang TY; Köhnke T; Thomas D; Linde M; Gars E; Stafford M; Kaur S; Nakauchi Y; Yin R; Azizi A; Narla A; Majeti R
    J Clin Invest; 2020 Apr; 130(4):1843-1849. PubMed ID: 31895700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects.
    Li Y; Liu L; Gomez D; Chen J; Tong Z; Palmisano M; Zhou S
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00436. PubMed ID: 30386625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.
    Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK
    Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of human nucleoside transporters in cellular uptake of 4'-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine.
    Clarke ML; Damaraju VL; Zhang J; Mowles D; Tackaberry T; Lang T; Smith KM; Young JD; Tomkinson B; Cass CE
    Mol Pharmacol; 2006 Jul; 70(1):303-10. PubMed ID: 16617163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA.
    MacBeth KJ; Chopra VS; Tang L; Zheng B; Avanzino B; See WL; Schwickart M; Figueroa ME; Quek L; DiMartino JF
    Exp Hematol; 2021 Jun; 98():47-52.e6. PubMed ID: 33794295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Structural and Molecular Features Involved in the Transport of 3'-Deoxy-Nucleoside Analogs by Human Equilibrative Nucleoside Transporter 3.
    Rahman MF; Raj R; Govindarajan R
    Drug Metab Dispos; 2018 May; 46(5):600-609. PubMed ID: 29530865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
    de Botton S; Brandwein JM; Wei AH; Pigneux A; Quesnel B; Thomas X; Legrand O; Recher C; Chantepie S; Hunault-Berger M; Boissel N; Nehme SA; Frattini MG; Tosolini A; Marion-Gallois R; Wang JJ; Cameron C; Siddiqui M; Hutton B; Milkovich G; Stein EM
    Cancer Med; 2021 Sep; 10(18):6336-6343. PubMed ID: 34427990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.
    Montesinos P; Fathi AT; de Botton S; Stein EM; Zeidan AM; Zhu Y; Prebet T; Vigil CE; Bluemmert I; Yu X; DiNardo CD
    Blood Adv; 2024 May; 8(10):2509-2519. PubMed ID: 38507688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enasidenib.
    Krämer A; Bochtler T
    Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.
    Stein EM
    Future Oncol; 2018 Jan; 14(1):23-40. PubMed ID: 29243965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of human nucleoside transporters in uptake of 3'-deoxy-3'-fluorothymidine.
    Paproski RJ; Ng AM; Yao SY; Graham K; Young JD; Cass CE
    Mol Pharmacol; 2008 Nov; 74(5):1372-80. PubMed ID: 18669604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.